Miscellaneous (e.g., Hydrocarbons, Etc.) Patents (Class 514/789)
-
Publication number: 20130245135Abstract: The invention is directed to methods and compositions for collecting a non-placental biological samples of cells and quantifying and comparing levels of expression of microRNAs to characterize a preeclampsia-related condition. The samples may be collected before or after an intervention or may be collected over a period of time. One of the samples may be a control sample. Patients may then be treated according to their response.Type: ApplicationFiled: May 21, 2013Publication date: September 19, 2013Inventors: Edward E. Winger, Jane L. Reed
-
Publication number: 20130244191Abstract: A combination cigarette lighter and eye-drop applicator wherein the eye-drop device is secured to the lighter by being press fit secured with plastic clips or secured by hollow housing, a reservoir in the housing adapted to hold a supply of eye-drops and a squeeze bottle for applying the eye-drops in addition to the fire-lighting section of ordinary lighters, such that a person could ease eye irritation and redness due to smoke or allergies without needing anything but a lighter.Type: ApplicationFiled: March 16, 2012Publication date: September 19, 2013Inventors: Jeffrey George Bush, Joshua Tyler Kay
-
Patent number: 8535707Abstract: Described here are devices, methods, and kits for treating sinusitis and related respiratory conditions by locally delivering active agents to the osteomeatal complex over a sustained period of time. The devices may be passively fixed within the osteomeatal complex and/or include one or more features that actively fix it within the osteomeatal complex. The devices may optionally include a portion that extends into a sinus ostium, sinus cavity, and/or the nasal passage to deliver an active agent.Type: GrantFiled: July 9, 2007Date of Patent: September 17, 2013Assignee: Intersect ENT, Inc.Inventors: Patrick A. Arensdorf, Danielle L. Biggs, Rodney Brenneman, David B. Downie, Donald J. Eaton, Thomas R. Tice
-
Publication number: 20130231404Abstract: The present invention features methods, devices, and systems, e.g., for providing diagnostic or treatment decision support to a clinician for the diagnosis or treatment of a patient in need thereof or for diagnosing or treating a patient in need thereof.Type: ApplicationFiled: February 28, 2013Publication date: September 5, 2013Applicant: SimulConsult, Inc.Inventor: Michael M. SEGAL
-
Patent number: 8519010Abstract: What is described herein are antimicrobial compositions which are defined blends of a 1,2-diol and phenoxyethanol which show broad activity against bacteria, fungi and mold spores. This activity is potentiated by the addition thereto of small amounts of a co-biocide for which the blend acts as a delivery system for the otherwise water-insoluble co-biocide.Type: GrantFiled: April 29, 2011Date of Patent: August 27, 2013Assignee: ISP Investments Inc.Inventors: John J. Merianos, Paul Garelick, Susan M. Lindstrom
-
Publication number: 20130203871Abstract: The invention is a herd management schema based upon the inventor's analysis of the natural history of bovine infection due to Mycobacterium avium subspecies paratuberculosis (Map) and related genomic variants and upon the ability of two distinct Map ELISA tests to sequentially or in parallel determine prior and current Map infection and evidence of active mycobacterium replication. Interpretation of the test results are integrated into sequential directives designed to enhance productive retention of infected animals as well as identify animals not previously infected. The sequential utilization of the data guidelines is developed to minimize the adverse economic impact of these infections.Type: ApplicationFiled: March 15, 2013Publication date: August 8, 2013Inventor: GILLES R.G. MONIF
-
Publication number: 20130203870Abstract: The present invention provides transgenic, large non-human animal models of atherosclerosis and hypercholesterolemia, as well as methods of using such animal models in the identification and characterization of therapies for atherosclerosis and hypercholesterolemia.Type: ApplicationFiled: September 23, 2012Publication date: August 8, 2013Inventors: Christopher S. Rogers, John R. Swart
-
Publication number: 20130197106Abstract: The invention relates to methods identifying compounds for the treatment of cell proliferation-related disorders, e.g., proliferative disorders such as cancer.Type: ApplicationFiled: March 31, 2011Publication date: August 1, 2013Applicant: AGIOS PHARMACEUTICALS, INCInventors: Valeria Fantin, Shin-San Michael Su
-
Publication number: 20130190277Abstract: A paraffin wax embedded drug delivery system is a method for combining topical medications with paraffin wax for enhanced delivery and absorption of the topical medication at a treatment area on a human body. A quantity of paraffin wax and a topical medication are provided, and mixture measurements are specified for a desired concentration and a desired ratio of ingredients for the mixture. To combine the topical medication and the paraffin wax, the quantity of paraffin wax is heated, the topical medication is added to the liquid paraffin wax, the mixture is agitated to ensure even combination, and the mixture is cooled. To apply the mixture, the mixture is heated back to its liquid state and applied to a treatment area using a wax bath, a brush, a roller, or another method.Type: ApplicationFiled: December 19, 2012Publication date: July 25, 2013Inventor: Joel Bain HERRON
-
Publication number: 20130178544Abstract: The present invention relates to methods for diagnosis or monitoring of viral infection by detecting the presence of transrenal viral nucleic acids or nucleic acids of viral origin in urine sample, with or without isolation of nucleic acids from a urine sample. The analysis of the nucleic acids is performed through hybridization of the nucleic acids with specific probes, or through a chain amplification reaction with specific primers. The methods are applicable to all viral pathogenic agents, including RNA, DNA, episomal, or integrated viruses.Type: ApplicationFiled: February 26, 2013Publication date: July 11, 2013Applicant: Trovagene, Inc.Inventors: Hovsep S. MELKONYAN, Angela Cannas, Louis David Tomei, Samuil R. Umansky
-
Publication number: 20130178543Abstract: A method of detecting a cancer stem cell or circulating tumor cell that has undergone epithelial-mesenchymal transition, comprising determining the level of caveolin-1 expressed by a sample cell, and comparing the level of caveolin-1 expressed by the sample cell to a control, wherein higher expression of caveolin-1 by the sample cell indicates that the sample cell is a cancer cell, as well as a method of detecting cancer or metastasis in a subject, and related methods and compositions.Type: ApplicationFiled: August 24, 2012Publication date: July 11, 2013Applicants: AJOU UNIVERSITY INDUSTRY COOPERATION FOUNDATION, SAMSUNG ELECTRONICS CO., LTD.Inventors: Yeon-jeong KIM, You-sun KIM, Jeong-gun LEE, Sang-hyun BAEK, Jin-mi OH, Hyo-young JEONG
-
Publication number: 20130172430Abstract: Methods of prognosis and monitoring of breast cancer include determining the level of one or more of the markers comprising asymmetric dimethyl arginine (ADMA), beta-hydroxybutyrate (BHB) and microRNA-31 (miR-31) in patient samples. An increased level is correlated with poor prognosis. Breast cancer is treated by administration of one or more inhibitors of ADMA and/or BHB.Type: ApplicationFiled: December 8, 2011Publication date: July 4, 2013Inventors: Michael P. Lisanti, Federica Sotgia
-
Publication number: 20130172431Abstract: Disclosed are methods for conducting diagnostic tests for the detection of the inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. Also described are methods for monitoring a patient by administering tests of the present invention. Also described are methods for monitoring patient's treatment by administering tests of the present invention. Also described are methods for evaluating the effectiveness of a drug or a drug candidate by administering tests of the present invention to samples from patients, animal models, and cell cultures treated with a drug or a drug candidate. Also disclosed are methods for determining the usefulness of analytes, e.g. cytokines, for acting as diagnostic and monitoring markers for inflammatory bowel disease in the various methods of the invention.Type: ApplicationFiled: February 25, 2013Publication date: July 4, 2013Applicant: Meso Scale Technologies, LLCInventors: Jeff D. Debad, Eli N. Glezer, Sudeep M. Kumar
-
Publication number: 20130150465Abstract: The present invention relates to a genetically modified pig as a model for studying breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex. The modified pig model displays one or more phenotypes associated with any of said disorders. Disclosed is also a modified pig comprising a modified endogeneous BRCA1 and/or BRCA2 gene, and/or a modified ornithine transcarbamylase gene, and/or a modified Keratin 14 gene and/or a transcriptional or translational product or part thereof. The invention further relates to methods for producing the modified pig; and methods for evaluating the effect of a therapeutical treatment of breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex; methods for screening the efficacy of a pharmaceutical composition; and a method for treatment of a human being suffering from breast cancer, mitochondria related protein folding disorders and/or epidermolysis bullosa simplex are disclosed.Type: ApplicationFiled: August 22, 2012Publication date: June 13, 2013Applicant: Aarhus UniversitetInventors: Peter Michael Kragh, Lars Axel Bolund, Charlotte Brandt Sørensen, Thomas Juhl Corydon, Niels Gregersen, Peter Bross
-
Publication number: 20130131194Abstract: The presently disclosed subject matter is directed to methods of aiding diagnosis, prognosis, monitoring and evaluation of a disease or other medical condition in a subject by detecting a biomarker in microvesicles isolated from a biological sample from the subject.Type: ApplicationFiled: November 29, 2012Publication date: May 23, 2013Applicant: THE GENERAL HOSPITAL CORPORATIONInventor: The General Hospital Corporation
-
Publication number: 20130131195Abstract: Objective quantitation of the c-Src protein directly in cancer patient tissue can aid in determining the aggressiveness of an individual patient's tumor as well as help make more informed decisions about choice of therapy. However, the c-Src protein is currently analyzed directly in formalin fixed patient tissue only by immunohistochemistry methodology which is at best subjectively semi-quantitative. This invention describes an objective quantitative assay for the c-Src protein using mass spectrometry as the analytical methodology. Specific peptides, experimentally discovered characteristics about the peptides, and experimentally established assay conditions based on those peptide characteristics are provided for use in a mass spectrometry-based Selected Reaction Monitoring (SRM) assay in order to measure relative or absolute quantitative levels of c-Src directly in a protein preparation obtained from a formalin fixed cancer patient tissue sample.Type: ApplicationFiled: January 30, 2013Publication date: May 23, 2013Applicant: EXPRESSION PATHOLOGY, INC.Inventor: Expression Pathology, Inc.
-
Publication number: 20130123605Abstract: Described herein are systems and methods of identifying bipolar disorder in a person. One such method includes acquiring 31P spectroscopic imaging data from a region of interest in a brain of the person and subsequently analyzing the 31P spectroscopic imaging data to obtain a signal intensity and a concentration for one or more phosphorus metabolites. A reduced concentration the one or more phosphorus metabolites, such as inorganic phosphate, in the brain can indicate bipolar disorder in the person. Frontal lobe inorganic phosphate concentration in medication-free adolescents can indicate bipolar depression.Type: ApplicationFiled: October 16, 2012Publication date: May 16, 2013Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventor: University of Utah Research Foundation
-
Publication number: 20130116343Abstract: A method of diagnosing a patient's risk of breast cancer comprises measuring in a saliva sample from the patient a concentration of at least a first protein marker, wherein the first protein marker is either ubiquitin or cytochrome p450, to provide a set of test data comprising a concentration value of each protein marker in the saliva sample. The test values are then compared to a reference panel comprising a Reference Control Value and a Reference Breast Cancer Value, and a diagnosis of either increased or decreased risk of breast cancer is determined for the patient based on a result of that comparison. A test kit for identifying a person at increased risk of breast cancer is also provided.Type: ApplicationFiled: April 21, 2011Publication date: May 9, 2013Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Charles F. Streckfus, William P. Dubinsky, Lenora Bigler, Karen A. Storthz, Daniel Arreola
-
Publication number: 20130116344Abstract: The present invention relates to the use of at least one nucleic acid comprising or consisting of: (i) (SEQ?ID?NO:?1) CATCGATGAAGAACGCWGCRAAHTGCGATAMGTARTGYGAATTGCAGR ATTCAGTGARTCATCGAAWYTTTGAACGCAYMTTGCRC, wherein: R represents A or G Y represents C or T M represents A or C W represents A or T H represents A or C or T (ii) a portion of SEQ ID NO: 1, provided said nucleic acid binds under stringent conditions to a nucleic acid comprising or consisting of the complementary sequence of SEQ ID NO: 1, or (iii) complementary sequences of (i) and (ii); for the detection of nucleic acids from one or more fungi in a sample.Type: ApplicationFiled: December 20, 2012Publication date: May 9, 2013Inventors: Nicola Di Maiuta, Patrick Schwarzentruber
-
Publication number: 20130102692Abstract: Disclosed are methods for diagnosis or prognosis of Alzheimer's disease in a patient. The methods may include assessing whether a patient has Alzheimer's disease or assessing a patient's risk for developing Alzheimer's disease. The methods typically include determining, either directly or indirectly, whether the patient has mutations, such as single nucleotide polymorphisms, in a plurality of genes that encode gene products that function in steroid biosynthesis.Type: ApplicationFiled: November 30, 2012Publication date: April 25, 2013Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventor: Wisconsin Alumni Research Foundation
-
Publication number: 20130102471Abstract: The present invention is a formula composition that acts as an efficient delivery system to transport active components to their desired target sites in the bodies of human, animal, or plant species. This formula composition is comprised of d-Limonene (C10H16), Glycol EB (2-Butoxyethanol), Calimulse PRS (Benzenesulfonic acid, C10-16-alkyl derivatives, compounds with 2-propanamine), Calsoft L-60 (Benzenesulfonic acid, C10-16-alkyl derivatives, sodium salts, Sodium xylene sulfonate, sodium sulfate), Isopar M Solvent (Light Hydrotreated Petroleum Distillates), and water. This formula composition has both pharmaceutical and agricultural product applications, due to its ability to emulsify certain active components, preserve active components in their intact form, quickly deliver them to their target sites in the body, and increase their absorptions.Type: ApplicationFiled: October 17, 2012Publication date: April 25, 2013Inventor: Huu Tieu
-
Publication number: 20130096212Abstract: The present invention relates to the method for predicting the pharmacoresponse of antidepressants in patients diagnosed with major depression and panic disorder. According to the invention, SNP (rs41271330) in the coding region of the BMP5 gene together with the markers in linkage disequilibrium with this SNP could be used as predictors of SSRI treatment efficacy. The knowledge obtained by using the method disclosed in present invention has potential to increase the efficacy of pharmacological treatment in patients with major depression and panic disorder. The invention also provides a kit for detecting individual who are likely to respond to antidepressant treatment.Type: ApplicationFiled: October 9, 2012Publication date: April 18, 2013Applicant: UNIVERSITY OF TARTUInventor: UNIVERSITY OF TARTU
-
Publication number: 20130079425Abstract: Specific peptides are provided that are derived from subsequences of the urokinase-type plasminogen activator protein and the plasminogen activator inhibitor type-1 protein along with assays that can measure those peptides directly in complex protein lysate samples, including protein lysates prepared from histologicaly-processed formalin fixed tissue. The presence and amount of those peptides in samples from a subject can be associated with disease, including cancer, in a subject and provide information about the diagnostic stage/grade/status of the disease/cancer.Type: ApplicationFiled: November 26, 2012Publication date: March 28, 2013Applicant: EXPRESSION PATHOLOGY, INC.Inventor: Expression Pathology, Inc.
-
Publication number: 20130079423Abstract: The invention relates generally to methods of molecular analysis and particularly to methods of using genetic copy number variations and loss of heterozygosity in the characterization and treatment of disease.Type: ApplicationFiled: February 24, 2011Publication date: March 28, 2013Applicant: Myriad Genetics, IncorporatedInventors: Victor Abkevich, Kirsten Timms, Alexander Gutin
-
Publication number: 20130079424Abstract: Using the methods of the present invention, intermediate (int) levels of aldehyde dehydrogenase (ALDH) activity reliably distinguished leukemic CD34+CD38? cells capable of engrafting immunodeficient mice, from residual normal hematopoietic stem cells that exhibited relatively higher ALDH activity. Minimal residual disease (MRD) detected during complete remission was enriched for the CD34+CD38?ALDHint leukemic cells, and the presence of these cells after therapy highly correlated with subsequent clinical relapse. The methods of the present invention can distinguish normal from leukemic CD34+CD38? cells, and identifies those AML cells associated with relapse. Methods of prediction of relapse of AML patients and methods of treatment are also provided.Type: ApplicationFiled: September 24, 2012Publication date: March 28, 2013Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Jonathan Michael Gerber, Richard John Jones
-
Publication number: 20130072582Abstract: The invention provides methods of diagnosing or determining a cause of an autoimmune encephalitis or an epilepsy in a subject and of diagnosing a tumor in a subject, comprising the step of testing a biological sample of the subject for an antibody to LGI1. This invention further provides methods of treating an autoimmune encephalitis or an epilepsy, comprising the steps of detecting an antibody to LGI1 and treating a tumor associated with the disease.Type: ApplicationFiled: May 11, 2011Publication date: March 21, 2013Inventor: Josep Dalmau
-
Publication number: 20130072581Abstract: The current disclosure provides for specific peptides from the Secreted Protein Acidic and Rich in Cysteine (SPARC) protein and the derived ionization characteristics of those peptides that are advantageous for quantifying SPARC directly in formalin fixed biological samples by the method of Selected Reaction Monitoring (SRM) mass spectrometry. Such fixed biological samples include: formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and formalin fixed and paraffin embedded tissue culture cells. SPARC protein is quantitated in biological samples by the method of SRM/MRM mass spectrometry by quantitating one or more of the peptides described herein. The peptides can be quantitated if they reside in a modified or an unmodified form. Examples of potentially modified forms of SPARC peptides include those bearing phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.Type: ApplicationFiled: June 21, 2012Publication date: March 21, 2013Inventors: David B. KRIZMAN, Todd Hembrough, Sheeno Thyparambil
-
Publication number: 20130072580Abstract: Methods for diagnosis of sepsis very low birth weight (VLBW) infants are disclosed. The diagnostic methods for sepsis are based on determining whether a bodily fluid sample, such as a urine sample, contains an amount of neutrophil gelatinase-associated lipocalin (NGAL) protein that exceeds or is less than a certain threshold level, or that falls within a certain range. The present invention also provides methods for monitoring the progression of sepsis, methods for monitoring sepsis treatment, methods of distinguishing between true-positive and false culture-positive sepsis, and kits for diagnosing sepsis in VLBW infants.Type: ApplicationFiled: April 30, 2012Publication date: March 21, 2013Inventors: Jonathan BARASCH, Elvira PARRAVICINI, David A. BATEMAN, John M. LORENZ
-
Patent number: 8399525Abstract: Provided is a method of monitoring the treatment of Gaucher disease with specific pharmacological chaperones using systemic and/or cellular surrogate markers. Also provided is a new biomarker that may be used to monitor the progress of such treatment.Type: GrantFiled: April 11, 2008Date of Patent: March 19, 2013Assignee: Amicus Therapeutics, Inc.Inventor: David J. Lockhart
-
Publication number: 20130065972Abstract: The present invention provides a method for screening for a Th2 inflammatory disease in a subject comprising the steps of: assaying a miR-21 expression level in a biological sample from the subject, and comparing the miR-21 expression level in the biological sample from the subject to the miR-21 expression level in a control, wherein an increase in the miR-21 expression level in the biological sample from the subject compared to the miR-21 expression level in the control indicates the presence of Th2 inflammatory disease in the subject.Type: ApplicationFiled: September 7, 2012Publication date: March 14, 2013Applicant: Indiana University Research and Technology CorporationInventors: Alexander L. Dent, Deepali Sawant
-
Publication number: 20130059931Abstract: The invention is directed to a cell comprising a nucleic acid encoding an Activation Induced Deaminase (AID) polypeptide, a fusion protein comprising an AID polypeptide, and methods of using a nucleic acid encoding an AID polypeptide.Type: ApplicationFiled: September 7, 2012Publication date: March 7, 2013Applicant: MEDICAL RESEARCH COUNCILInventors: Svend K. Petersen-Mahrt, Reuben Harris, Michael S. Neuberger, Rupert Christopher Landsdowne Beale
-
Publication number: 20130059930Abstract: The invention provides a method of detecting a subject suffering from, or at risk of suffering from, bladder cancer the method comprising i) providing a body fluid sample isolated from a subject; ii) isolating cells from said sample to provide a cell sample; iii) contacting the sample with a specific binding member capable of binding to a minichromosome maintenance (MCM) polypeptide(s); iv) determining the binding of said specific binding member to the cell sample; v) counting those cells in said cell sample which bound to said specific binding member to provide a cell count; vi) determining, based on the cell count, whether the subject has, or is at risk of having, bladder cancer.Type: ApplicationFiled: January 6, 2012Publication date: March 7, 2013Applicant: Cytosystems LimitedInventors: David Galloway, Nick Coleman
-
Publication number: 20130052149Abstract: The disclosed invention relates to a process, comprising: conducting unit operations in at least two process zones in a process microchannel to treat and/or form a non-Newtonian fluid, a different unit operation being conducted in each process zone; and applying an effective amount of shear stress to the non-Newtonian fluid to reduce the viscosity of the non-Newtonian fluid in each process zone, the average shear rate in one process zone differing from the average shear rate in another process zone by a factor of at least about 1.2.Type: ApplicationFiled: October 4, 2012Publication date: February 28, 2013Applicant: VELOCYS, INC.Inventor: Velocys, Inc.
-
Publication number: 20130041047Abstract: A method of detecting bladder cancer is described using hypermethylated urinary markers.Type: ApplicationFiled: June 1, 2012Publication date: February 14, 2013Applicant: AROS APPLIED BIOTECHNOLOGY ASInventors: Torben Falck Ørntoft, Lars Dyrskjøt Andersen, Jørgen Thomas Reinert, Charlotte Modin, Philippe Lamy
-
Patent number: 8372824Abstract: Compounds exhibiting 3alpha-hydroxy-5alpha/beta-steroid blocking action with no or only low antagonism against the gamma-aminobutyric acid (A) receptor (GABA-A), and compounds exhibiting partial antagonism against said receptor are presented. Methods for the prevention, treatment and/or alleviation of various CNS-disorders are suggested, as well as pharmaceutical compositions for such use.Type: GrantFiled: February 13, 2012Date of Patent: February 12, 2013Assignee: Umecrine ABInventors: Torbjorn Backstrom, Per Lundgren, Ming-De Wang
-
Publication number: 20130035404Abstract: Genome-wide analysis of copy number changes in breast and colorectal tumors used approaches that can reliably detect homozygous deletions and amplifications. The number of genes altered by major copy number changes—deletion of all copies or amplification of at least twelve copies per cell—averaged thirteen per tumor. These data were integrated with previous mutation analyses of the Reference Sequence genes in these same tumor types to identify genes and cellular pathways affected by both copy number changes and point alterations. Pathways enriched for genetic alterations include those controlling cell adhesion, intracellular signaling, DNA topological change, and cell cycle control. These analyses provide an integrated view of copy number and sequencing alterations on a genome-wide scale and identify genes and pathways that are useful for cancer diagnosis and therapy.Type: ApplicationFiled: May 1, 2012Publication date: February 7, 2013Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Bert VOGELSTEIN, Kenneth W. KINZLER, Rebecca J. LEARY, Victor E. VELCULESCU
-
Patent number: 8367108Abstract: The present invention relates to compound of formula I, which are functionalized, non-phenolic amino acids, and polymers formed from the same. Polymers formed from the functionalized amino acids are expected to have controllable degradation profiles, enabling them to release an active component over a desired time range. The polymers are also expected to be useful in a variety of medical applications.Type: GrantFiled: August 29, 2007Date of Patent: February 5, 2013Assignee: Bezwada Biomedical, LLCInventor: Rao S. Bezwada
-
Publication number: 20130012604Abstract: Methods of predicting the development of medically refractory ulcerative colitis (MR-UC) in a patient by determining the presence or absence of one or more risk variants, where the presence of one or more risk variants is indicative of a severe and/or aggressive form of ulcerative colitis are disclosed.Type: ApplicationFiled: March 16, 2011Publication date: January 10, 2013Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Jerome I. Rotter, Kent D. Taylor, Stephan R. Targan
-
Publication number: 20130012603Abstract: The studies described herein demonstrate that ?? fibrinogen and total fibrinogen are independent risk factors for cardiovascular disease. Further described herein is the unexpected finding that an elevated concentration of ?? fibrinogen in combination with an elevated concentration of total fibrinogen is a significantly better predictor of cardiovascular disease risk than either marker alone. Thus, provided herein are methods of detecting a subject having cardiovascular disease, or at increased risk of developing a cardiovascular disease, by measuring both the concentration of ?? fibrinogen and the concentration of total fibrinogen in a sample obtained from the subject.Type: ApplicationFiled: March 8, 2011Publication date: January 10, 2013Inventor: David H. Farrell
-
Publication number: 20130012602Abstract: The present invention relates to prognosing, diagnosing and treating of Crohn's disease.Type: ApplicationFiled: January 13, 2011Publication date: January 10, 2013Applicant: CEDARS-SINAI MEDICAL CENTERInventors: Talin Haritunians, Jerome I. Rotter, Kent D. Taylor, Stephan R. Targan
-
Publication number: 20130005837Abstract: Described herein are methods for predicting recurrence, progression, and metastatic potential of a prostate cancer in a subject. In certain embodiments, the methods comprise analyzing a sample from a subject for aberrant expression patters of one or more biomarkers disclosed herein. An increase or decrease in one or more biomarkers as compared to a standard indicates a recurrent, progressive, or metastatic prostate cancer.Type: ApplicationFiled: December 29, 2010Publication date: January 3, 2013Applicant: Emory UniversityInventors: Carlos Moreno, Qi Long, Benjamin G. Barwick
-
Publication number: 20130004602Abstract: A lotion composition containing a microcrystalline wax, a fibrous structure containing such lotion composition and a method for making such fibrous structure and/or lotion composition are provided.Type: ApplicationFiled: June 29, 2012Publication date: January 3, 2013Inventors: Michael Raymond Mootz, Angela Marie Leimbach
-
Publication number: 20130005836Abstract: Compositions and methods related to diagnosis of ear infections and acute otitis media.Type: ApplicationFiled: June 4, 2012Publication date: January 3, 2013Inventors: Michael Pichichero, Kyle Liu
-
Patent number: 8343533Abstract: The present invention features a process for making a lozenge product including the steps of forming a powder blend containing an amorphous carbohydrate polymer into the desired shape of the lozenge product and applying radiofrequency energy to the shape for a sufficient period of time to soften or melt said amorphous carbohydrate polymer to fuse the shape into said lozenge product.Type: GrantFiled: September 22, 2010Date of Patent: January 1, 2013Assignee: McNeil-PPC, Inc.Inventors: Jen-Chi Chen, Harry S. Sowden, Joseph R. Luber, Leo B. Kriksunov, Frank J. Bunick, Christopher E. Szymczak, Gregory E. Koll
-
Publication number: 20120329886Abstract: The invention provides, in certain embodiments, a method of detecting an indicator of renal injury or renal disease. The method entails assaying a urine sample for periostin, wherein the presence of periostin at an elevated level indicates the presence and/or degree of renal injury or renal disease. Also provided, are methods of determining progression of these conditions, as well as methods of determining subjects' response to treatment.Type: ApplicationFiled: August 9, 2012Publication date: December 27, 2012Applicant: Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterInventors: Sharon Adler, Bancha Satirapoj, Ying Wang, Janine LaPage, Cynthia C. Nast
-
Publication number: 20120302649Abstract: The present invention provides a method for screening and evaluating ameliorants of dry skin caused by atopic dermatitis, comprising: evaluating a candidate drug as being an ameliorant of dry skin caused by atopic dermatitis in the case the candidate drug significantly increases expression and/or activity of bleomycin hydrolase in comparison with a control drug.Type: ApplicationFiled: December 2, 2010Publication date: November 29, 2012Inventors: Toshihiko Hibino, Yayoi Kamata, Mami Yamamoto
-
Publication number: 20120302650Abstract: The current disclosure provides for specific peptides from the Insulin-Like Growth Factor 1 Receptor (IGF-1R) protein and the derived ionization characteristics of those peptides that are advantageous for quantifying the IGF-1R directly in formalin fixed biological samples by the method of Selected Reaction Monitoring (SRM) mass spectrometry. Such fixed biological samples include: formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and formalin fixed and paraffin embedded tissue culture cells. IGF-1R protein is quantitated in biological samples by the method of SRM/MRM mass spectrometry by quantitating one or more of the peptides described herein. The peptides can be quantitated if they reside in a modified or an unmodified form. Examples of potentially modified forms of an IGF-1R peptides include those bearing phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.Type: ApplicationFiled: June 21, 2012Publication date: November 29, 2012Applicant: EXPRESSION PATHOLOGY, INC.Inventors: David B. Krizman, Todd Hembrough, Sheeno Thyparambil
-
Publication number: 20120294926Abstract: The present invention is drawn to adhesive formulations and methods of drug delivery. The formulation can include a drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system including at least two volatile solvents, and a non-volatile solvent system including at least one non-volatile solvent, wherein at least one non-volatile solvent is capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.Type: ApplicationFiled: August 3, 2012Publication date: November 22, 2012Inventors: Jie Zhang, Kevin S. Warner, Sanjay Sharma
-
Publication number: 20120295990Abstract: The current disclosure provides for specific peptides from the Insulin Receptor Substrate 1 (IRS1) protein and the derived ionization characteristics of those peptides that are advantageous for quantifying IRS1 directly in formalin fixed biological samples by the method of Selected Reaction Monitoring (SRM) mass spectrometry. Such fixed biological samples include: formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and formalin fixed and paraffin embedded tissue culture cells. IRS1 protein is quantitated in biological samples by the method of SRM/MRM mass spectrometry by quantitating one or more of the peptides described herein. The peptides can be quantitated if they reside in a modified or an unmodified form. Examples of potentially modified forms of IRS1 peptides include those bearing phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.Type: ApplicationFiled: June 21, 2012Publication date: November 22, 2012Applicant: EXPRESSION PATHOLOGY, INCInventors: David B. KRIZMAN, Todd Hembrough, Sheeno Thyparambil
-
Publication number: 20120277326Abstract: Methods for diagnosis and staging of ovarian cancer, based on relative immunoreactivity of different IgG subclasses of autoantibodies, autoantibodies to defined antigens, e.g., antigens with specific subcellular localization, are described.Type: ApplicationFiled: November 19, 2010Publication date: November 1, 2012Inventors: Douglas D. Taylor, Cicek Gercel-Taylor